COVID-19 Vaccination Is Needed in Patients With Cancer to Enable Optimal Treatment Delivery
Balazs Halmos, MD, discusses findings from a study he participated on, which found that COVID-19 vaccination induced high rates of seroconversion in patients with cancer, although those with hematologic malignancies had lower immunogenicity and those who received prior immunosuppressive therapies appeared to be less responsive.
Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
June 24th 2021Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.
COVID-19 vaccination has been shown to induce high rates of seroconversion in patients with cancer, although those with hematologic malignancies have demonstrated lower immunogenicity and those who previously received immunosuppressive therapies appear to be less responsive.
